secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001193125-25-291979
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage achieves first OpRegen milestone under Roche deal; $5M payment triggered
--------------------------------------------------------------------------------

- First development milestone under Roche Agreement for OpRegen (RG6501) achieved; $5M payment triggered.
- Payment expected within 30 days; net proceeds after ~24.1% to Israel Innovation Authority and ~21.5% to Hadasit.
- OpRegen is being evaluated in Phase 2a GAlette trial for geographic atrophy secondary to AMD.
- Milestone based on manufacturing and clinical advancements in the OpRegen cell therapy program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000119312525291979/0001193125-25-291979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000119312525291979/lctx-20251120.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-291979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer